[Inhibition of angiogenesis in pancreatic carcinoma by cyclooxygenase-2 antisense oligodeoxynucleotides]

Xing-Peng Wang1, Chuan-Gao Xie, Yu-Wei Dong

  • 1Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China.

Zhonghua Yi Xue Za Zhi
|October 3, 2003
PubMed
Abstract

Insights

Cyclooxygenase-2 antisense oligodeoxynucleotides (COX-2 AS-ODNs) effectively inhibit pancreatic cancer angiogenesis. Prostaglandin E2 (PGE2) appears to play an intermediate role in this process, highlighting a potential therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Context:

  • Pancreatic carcinoma is a highly aggressive malignancy with limited treatment options.
  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
  • Cyclooxygenase-2 (COX-2) is implicated in promoting tumor angiogenesis.

Purpose:

  • To investigate the anti-angiogenic effects of COX-2 antisense oligodeoxynucleotides (AS-ODNs) in pancreatic cancer.
  • To elucidate the role of prostaglandin E2 (PGE2) as an intermediary in COX-2 AS-ODN-mediated angiogenesis inhibition.

Summary:

  • Specific COX-2 AS-ODNs were synthesized and transfected into PC3 human pancreatic carcinoma cells.
  • RT-PCR and Western blotting confirmed dose- and time-dependent downregulation of COX-2 mRNA and protein expression.
  • In vivo studies on chicken chorioallantoic membranes demonstrated significant inhibition of tumor angiogenesis by COX-2 AS-ODNs.

Impact:

  • COX-2 AS-ODNs demonstrate significant potential as a therapeutic strategy to inhibit pancreatic cancer angiogenesis.
  • The findings suggest that targeting COX-2 signaling, potentially involving PGE2, could be a viable approach for pancreatic cancer treatment.
  • This research provides a foundation for further investigation into the clinical application of AS-ODN therapy for pancreatic cancer.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...